Vice President, Clinical Development, Danicamtiv (DANI)

About Us Kardigan is a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world. Kardigan’s mission is to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases to the cures they deserve. Kardigan was founded by leaders who previously discovered and developed mavacamten, the first cardiac myosin inhibitor, which was acquired by Bristol Myers Squibb in 2020. We have a cutting‑edge discovery and translational research platform, a pipeline of late‑stage candidates, and an industry‑leading team dedicated to improving patients’ lives. Kardigan is guided by values that emphasize authentic leadership, curiosity, teamwork, urgency, and innovation to enable the impossible for patients. Role Overview The VP, Clinical Development will serve as Clinical Lead, responsible for clinical development strategy and execution across one or more programs. Key Responsibilities Serve as Clinical Lead for the Danicamtiv program, with end‑to‑end accountability for clinical strategy and execution, including protocol development, regulatory interactions, and approval. Lead the Danicamtiv Clinical Strategy Team with cross‑functional leadership in development and execution of the program plan. Own clinical development plans and protocol design, providing critical input for indication selection and target product profile (TPP). Make clinical decision‑making based on emerging data, benefit–risk assessments, and evolving regulatory expectations. Act as primary clinical development point of contact for regulatory interactions, investigators, and key opinion leaders related to the Danicamtiv program. Collaborate with Clinical Operations, Biometrics, Regulatory, and Medical Affairs to ensure seamless oversight and execution of clinical trials. Represent Kardigan at scientific meetings, advisory boards, and interactions with KOLs related to Danicamtiv and other drug programs. Present clinical strategy, study progress, and risks to internal leadership, Executive Committee, and Board of Directors as needed. Qualifications MD (or equivalent) with board certification and clinical practice experience in cardiology strongly preferred. 15+ years in clinical development within biotech/pharma, preferably in cardiomyopathy/heart failure drug development. Experience serving as clinical lead for a major drug program with key late‑stage milestones. Strong understanding of cardiovascular trial designs, endpoints, and regulatory strategies. Well‑developed relationships with key external experts in cardiomyopathy/heart failure and track record of overseeing external research collaborations. Experience with genetic screening initiatives for clinical research and care delivery desired. Proven ability to influence and lead cross‑functional teams. Experience in late‑stage development and/or regulatory submissions. Prior experience managing or mentoring other MDs. Experience in a high‑growth or emerging biotech environment. Track record of effective partnership with a CMO or senior medical leadership. Leadership Characteristics Highly credible clinical development leader with strong clinical judgment. Strategic thinker who balances rigor with speed and pragmatism. Strong collaborator and people leader with extensive experience building and leading teams. Comfortable operating in ambiguity and designing future‑state organizations. Compensation Pay range: $340,000 - $416,000 USD (exact compensation may vary based on skills, experience, and location). #J-18808-Ljbffr Kardigan